In the United States, it is estimated that in a single year more than 180,000 women will be diagnosed with breast cancer and roughly 40,000 women will die. Our client and partner, Cyrcadia Health (formerly First Warning Systems), has developed a non-invasive and nonradiogenic system for the early detection of tissue abnormalities. The system has proven highly effective for use with young women and eliminates barriers to access for low-income women and for women with a family history of breast cancer who require more frequent testing. It costs much less than current screening methods requiring mammogram or MRI equipment.
The system uses data collected from deep tissue thermal sensors arrayed across both breasts and has a strong track record in three clinical trials. Cyrcadia Health requires an analytic technology to develop accurate detection models from complex sensor data, and to deploy automated screening scores to millions of customers on an ongoing basis.